CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
AssigneeTanox, Inc.
InventorNancy T. Chang
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of stimulating antibody-dependent cellular cytotoxicity to enhance the elimination of IgE-bearing B-cells comprising administering to a mammal an anti-IgE antibody, which binds to membrane bound IgE, but does not induce histamine release and administering an ISO to the mammal. The ISO may be a CpG containing oligonucleotide, or a modified CpG-containing oligonucleotide with an electron-withdrawing group at least at position C-5 of the cytosine in the CpG sequence. In addition, the method may include the administration of an allergen to improve desensitization therapy.
Claims9
A method of stimulating antibody dependent cellular cytotoxicity (“ADCC”) to enhance the elimination of IgE-bearing B cells comprising:
- administering to a mammal an anti-IgE antibody which binds to membrane bound IgE, but does not induce histamine release;
- and
- administering an immune stimulatory oligonucleotide (“ISO”) to the mammal.
Dependencies are inferred from the claim text.